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Abstract
Summary Our findings show that only about 20 % of seniors
receive vitamin D supplementation prior to their index hip
fracture or after the event. We further confirm the high prev-
alence of severe vitamin D deficiency in this population and
show that those who receive supplementation have signifi-
cantly higher 25-hydroxyvitamin D (25(OH)D) status.
Introduction The aim of this study is to assess current
practice in pre- and post-hip fracture care practice with
respect to vitamin D supplementation.
Methods We surveyed 1,090 acute hip fracture patients age
65 and older admitted to acute care for hip fracture repair;
844 had serum 25-hydroxyvitamin D levels measured upon
admission to acute care, and 362 agreed to be followed at
12 month after their hip fracture. Prevalence of vitamin D
supplementation was assessed upon admission to acute care
(at the time of hip fracture), upon discharge from acute care,
and at 6 and 12 months follow-up.
Results Of 1,090 acute hip fracture patients (mean age
85 years, 78 % women, 59 % community-dwelling), 19 %
had received any dose of vitamin D prior to the index hip
fracture, 27 % (of 854 assessed) at discharge from acute care,
22 % (of 321 assessed) at 6 month, and 21% (of 285 assessed)
at 12 month after their hip fracture. At the time of fracture,
45 % had 25(OH)D levels below 10 ng/ml, 81 % had levels
below 20 ng/ml, and 96% had levels below 30 ng/ml. Notably,
25(OH)D levels did not differ by season or gender but were
significantly higher among 164 hip fracture patients, with any
vitamin D supplementation compared with 680 without sup-
plementation (19.9 versus 10.8 ng/ml; p<0.0001).
Conclusion Only about 20 % of seniors receive vitamin D at
the time of their fracture and after the event. This is despite
the documented 81 % prevalence of vitamin D deficiency.
Interdisciplinary efforts may be warranted to improve vita-
min D supplementation in seniors both before a hip fracture
occurs and after.
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Introduction
Hip fractures are the most common fractures among seniors
age 75 and older [1, 2]. Hip fractures are also the most
serious fractures: up to 50 % of seniors will have a perma-
nent functional disability; and within the first 12 month after
the fracture, 30–50 % will be readmitted to acute care [3], 15
to 30 % will require long-term nursing home care, and up to
20 % will die [1, 3–6]. The exponential increase in hip
fractures after age 75 translates into an estimated 1 in 3
women and 1 in 6 men, who will have sustained a hip
fracture by their 90th decade [7]. Consequently, with the
increase of the senior segment of the population, hip frac-
tures account for substantial and increasing health care
expenses, both in the US [8] and in Europe [9–11].
Supplemental vitamin D has been shown to reduce both
falls [12] and hip fractures [13] by about 30 %, summarized
in recent meta-analyses of double-blind randomized clinical
trials (RCTs), a benefit documented in community-dwelling
and institutionalized older seniors. Notably, both in the
meta-analysis of 8 RCTs among 2,426 seniors on fall pre-
vention [12] and the pooled analysis of participant level data
of 11 RCTs among 31,022 seniors on fracture prevention
[12], there was a dose threshold of about 800 IU vitamin D
per day required for the effective reduction of both end-
points. This is consistent with recommended vitamin D
intake by the institute of medicine [14], the international
osteoporosis foundation [15, 16], the US endocrine society
[17], and the Swiss department of health [18].
It is thus concerning that despite the existing evidence
with respect to vitamin D reflected in recent recommenda-
tions, the prevalence of vitamin D deficiency among hip
fracture has been found to be about 80 %, with 60 %
meeting the criteria of severe vitamin D deficiency (serum
concentrations below 10 ng/ml) [19, 20]. Notably, severe
vitamin D deficiency may cause osteomalacia [21], and
histologic osteomalacia has been found to be common in
several hip fracture case studies (12–44 %) [22–27].
In this study, we review the clinical application of vita-
min D supplementation in a large sample of acute hip
fracture patients before and after hip fracture. We also assess
their serum 25-hydroxyvitamin D (25(OH)D) concentra-
tions upon admission to acute care, explore seasonal varia-
tions for these concentrations, and investigate whether sub-
groups of hip fracture patients are more likely to receive
supplementation with vitamin D. Finally, to further under-
stand clinical practice procedures, we ask general practi-
tioners why they did not prescribe vitamin D after the hip
fracture event.
Methods
Participants
We surveyed all consecutive 1,090 acute hip fracture
patients aged 65 or older, who were admitted to one
large hospital center (Triemli City Hospital, Zurich,
Switzerland) between January 2005 and March 2010.
The survey was done as a part of screening procedure
for a clinical trial of early rehabilitation after hip frac-
ture [3]. Of the screened hip fracture patients, 173 were
eligible and agreed to participate in the clinical trial; the
details of the trial design and its inclusion/exclusion
criteria were published elsewhere [3]. All other patients
were offered participation in a cohort study (hip fracture
cohort), and 362 agreed to be followed for 1 year, with
2 phone calls at 6 (information on bone-related thera-
pies) and 12 months (full follow up phone call) after
their hip fracture. To evaluate the reasons why hip
fracture patients do not receive vitamin D after their
hip fracture, we performed a small substudy among
the 263 cohort participants, who were not receiving
supplemental vitamin D at discharge from the hospital.
We contacted these people 6 months after their hip
fracture, and asked whether they were prescribed vita-
min D supplements. Of 252 seniors who denied pre-
scription of vitamin D, we identified the primary phy-
sician in 143, and sent these primary physicians a
simple questionnaire to evaluate why they did not pre-
scribe vitamin D supplementation. Of 143 letters sent
out to general practitioners, we received a response
from 118 (83 %). For their response, general practi-
tioners received a small reimbursement of 20 Swiss
Francs. Our study was approved by the ethical commis-
sion at the Kanton Zurich, and participants gave their
written informed consent.
Variables
For all screened hip fracture patients: those who participated
in the clinical trial (n=173), those who participated in the
cohort (n=362), and those who did not participate in either
(n=555), demographic characteristics were abstracted from
the medical records. Cognitive function of all patients was
assessed with the mini mental state examination [28] during
acute care after hip fracture repair. Detailed information on
received medications was recorded at baseline for all
participants, and at discharge, and 12 months only for
the cohort participants. The 173 trial participants re-
ceived 800 or 2,000 IU vitamin D per day as the
intervention over a 12 month follow-up [3] and were
excluded from the post-hip fracture vitamin D supple-
mentation assessment. Medication information including
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vitamin D supplements was evaluated and cross-checked
by two investigators (S.M.; A.E.).
25-Hydroxyvitamin D measurement
Serum samples for 25-hydroxyvitamin D measurement were
available from 844 of 1,090 acute hip fracture patients. All
samples were analyzed at the Institute of Clinical Chemistry
at the University of Zurich using the automated DiaSorin
Liaison assay for the 25-hydroxyvitamin D assessment.
Statistical analysis
Participants of the clinical trial, the cohort study, and the
patients who were surveyed but did not participate in the
trial or the cohort were compared with respect to important
potential confounders using one-way ANOVA for continu-
ous and χ2 test for categorical variables.
Information from all 1,090 patients was used to evaluate
factors that could prevent seniors from receiving vitamin D
supplementation before their hip fracture. The patients
recruited for the clinical trial (n=173) received vitamin D
supplementation as a part of their study treatment and were
excluded from the analyses of the risk factors at discharge.
Only those who participated in the hip fracture cohort (n=
362) were followed up beyond discharge, so the analyses for
the 12-month time point was limited to these participants
only. During the 12-month follow up, 34 cohort participants
died, and 43 dropped out or were lost to follow up, bringing
the sample size at 12 months to n=285.
Logistic regression was used to evaluate associations
between population characteristics and the likelihood of
receiving any vitamin D supplementation and the minimum
recommended dose of vitamin D (800 IU). A separate model
was fitted for each of the investigated time points: admis-
sion, discharge, and 12 months after the fracture.
All statistical analyses were performed in SAS v. 9.2
statistical software (Copyright© 2002–2008 by SAS
Institute Inc., Cary, NC, USA), and two-sided p value of
0.05 was used as a threshold for statistical significance.
Results
Descriptive
Table 1 summarizes the three groups of acute hip fracture
patients (173 trial participants, 362 hip fracture cohort partici-
pants, and 555 hip fracture patients who were not recruited for
either), with respect to important potential confounders. Hip
fracture patients were on average 85.1(SD=7.1)years old, 78%
werewomen,mean bodymass indexwas 23.2(SD=4.3)kg/m2,
48 % had moderate to severe cognitive function impairment
(mini mental examination score <15; the classic diagnostic
range for the MMSE is 0–10=severe cognitive impairment,
11–20=moderate cognitive impairment, 21–26=mild cogni-
tive impairment, and 27–30=normal [29]), 59 % of patients
lived at home before the index hip fracture, and 54 % were
discharged to their home, after the fracture has been repaired.
25-Hydroxyvitamin D serum concentrations
Upon admission to acute care and reflecting serum
25(OH)D concentration at the time of their hip fracture,
mean 25(OH)D concentrations were 12.6(SD=8.7)ng/ml
among 844 seniors, with measurements; 96 % of study
participants had serum vitamin D levels below 30 ng/ml
(threshold of optimal fracture reduction [13, 15, 17, 30]),
80 % had levels below 20 ng/ml (deficiency [14]), and 52 %
had levels below 10 ng/ml (severe deficiency [21]). Notably,
as illustrated in Fig. 1, there were no significant seasonal
variations of serum 25(OH)D concentration (p=0.30) in this
sample of seniors with acute hip fracture, and levels did not
differ by gender (199 men had a mean level of 11.8 ng/ml,
645 women had a mean level of 12.8 ng/ml; p=0.10).
However, 164 hip fracture patients who received any dose
of vitamin D supplementation had significantly higher
25(OH)D serum concentrations compared with 680 without
supplementation (19.9 versus 10.8 ng/ml; p<0.0001).
Prevalence of vitamin D supplementation
Only 19 % of the acute fracture patients received vitamin D
at the time of their hip fracture. The proportion of patients
who were prescribed vitamin D increased to 27 % at dis-
charge, then fell back to 22 % at 6 months and 21 % at
12 month follow-up (Table 2 and Fig. 2). The most common
treatment strategy was vitamin D plus calcium supplemen-
tation, and very few patients received additional pharmaco-
logic treatment (Table 2). Of those who received vitamin D
supplementation, the current recommendation of 800 IU per
day was only received by 55 % prior to the index hip
fracture, by 57 % at discharge, by 55 % at 6 months, and
by 47 % at 12 month follow-up.
Women were prescribed vitamin D more often than men,
before their index hip fracture and at discharge from acute
care, as well as at 12 month follow-up (OR=2.26; 95 % C.I.
1.45–3.53, OR=1.78; 95 % C.I. 1.17–2.70, and OR=2.61;
95 % C.I. 1.04–6.55, respectively; Table 3). The association
between female gender and prevalence of vitamin D sup-
plementation was significant at all time points and indepen-
dent of age, cognitive function, and type of dwelling.
The association between type of dwelling and prevalence
of vitamin D supplementation varied with time. Before the
index hip fracture, seniors were equally likely to receive
vitamin D supplementation, regardless of whether they lived
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at home or in a nursing home. However, after the index hip
fracture, patients who were discharged to a nursing home
were only half as likely to receive vitamin D supplementa-
tion compared to those who were discharged home (OR=
Table 1 Characteristics of study population
Characteristic Clinical trial (n=173) Hip fracture cohort
participants (n=362)
Screened only
(n=555)
p† All n=1,090)
Women 137 284 427 0.77 848
(79.2 %) (78.5 %) (76.9 %) (77.8 %)
Age, years. 84.2 84.4 85.8 0.002 85.1
(6.9) (7.0) (7.1) (7.1)
Body mass index, kg/m2 24.3 23.6 22.6 <0.0001 23.2
(4.3) (4.1) (4.3) (4.3)
Mini mental examination score¶
<15 0 143 379 <0.0001‡ 522
(0 %) (39.5 %) (68.3 %) (48.0 %)
15+ 170 219 176 565
(100 %) (60.5 %) (31.7 %) (52.0 %)
Admitted from
Home 134 217 290 <0.0001 641
(77.5 %) (60.1 %) (52.7 %) (59.1 %)
Nursing/old age home 39 144 260 443
(22.5 %) (39.9 %) (47.3 %) (40.9 %)
Discharged to
Home (inkl. rehab.) 133 212 243 <0.0001 588
(76.9 %) (58.7 %) (44.3 %) (54.3 %)
Nursing/old age home 37 146 247 430
(21.4 %) (40.4 %) (45.0 %) (39.7 %)
Deceased during acute care 3 3 59 65
(1.7 %) (0.9 %) (10.7 %) (6.0 %)
Length of acute hospitalization, days 12.5 16.7 15.9 0.27 15.6
(8.8) (29.5) (31.08) (28.6)
Serum 25(OH)D level, ng/ml** at the
time of hip fracture
12.6 13.1 12.3 0.50 12.6
(7.9) (8.5) (9.0) (8.7)
Categories of serum 25(OH)D level**
<10 ng/ml 76 136 224 0.17 436
(45.2 %) (50.0 %) (55.5 %) (51.7 %)
10–19 ng/ml 59 79 107 245
(35.1 %) (29.0 %) (26.5 %) (29.0 %)
20–29 ng/ml 29 46 54 129
(17.3 %) (16.9 %) (13.3 %) (15.3 %)
30+ng/ml 4 11 19 34
(2.4 %) (4.1 %) (4.7 %) (4.0 %)
Any dose of vitamin D prior to index hip fracture
Yes 19 75 112 0.01 206
(11.0 %) (20.7 %) (20.2 %) (18.9 %)
No 154 287 442 883
(89.0 %) (79.3 %) (79.8 %) (81.1 %)
(Asterisk) continuous variables are given as mean (SD), categorical variables—as frequency (percentage), (dagger) based on one-way ANOVA for
continuous variables, χ2 -test for categorical variables, (pilcrow sign) MMSE data on three clinical trial participants are missing, (double dagger) P
value compares cohort participants to screened only patients (173 clinical trial participants are excluded from the analysis), and (double asterisk)
serum 25(OH)D concentrations were measured in 844 participants: clinical trial n=168, cohort study n=272, and screened patients n=404
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0.50; 95 % C.I. 0.35–0.71); and also at 12 months, nursing
home residents were 59 % less likely to receive vitamin D
supplementation compared to seniors living at home at this
time, although this did not reach statistical significance (OR
=0.63; 95 % C.I. 0.30–1.32; Table 3). Higher age and lower
cognitive function were not significant barriers for receiving
vitamin D supplementation at any time point (Table 3).
Why general practitioners did not prescribe vitamin D
supplementation after hip fracture
In a small substudy at 6 month follow-up, we identified 252
participants of the cohort study who were not supplemented
with vitamin D. Furthermore, we identified and sent letters
to 143 of their general practitioners, including a short
Fig. 1 Average serum 25(OH)D concentration at the time of hip
fracture and by month of measurement. Dots represent the average
25(OH)D serum concentration at the time of hip fracture (admission to
acute care) in ng/ml and by month of measurement. Whiskers depict
one standard deviation above and below the monthly average
Table 2 Prevalence of vitamin
D supplementation at the time of
hip fracture, at discharge from
acute care, and at 6 and
12 month follow-up
(Asterisk) clinical trial partici-
pants and patients who died in
hospital are excluded. (Dagger)
limited to cohort study partici-
pants only
Treatment At time of hip
fracture
At discharge from acute
care
6 months 12 months
(n=1,090) (n=854)* (n=321)† (n=285)†
No vitamin D supplement 884 628 252 226
(81.1 %) (73.5 %) (78.5 %) (79.3 %)
Vitamin D only 1 3 2 3
(0.1 %) (0.3 %) (0.6 %) (1.1 %)
Vitamin D and calcium 161 174 56 45
(14.8 %) (20.4 %) (17.4 %) (15.8 %)
Vitamin D and
bisphosphonate
2 3 0 1
(0.2 %) (0.3 %) (0 %) (0.4 %)
Vitamin D alone or in
combination
206 226 69 59
(18.9 %) (26.5 %) (21.5 %) (20.7 %)
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questionnaire for them to state why they did not prescribe
vitamin D to their patients who had a hip fracture. Of 143
letters sent out, we got a response from 118 (83 %) general
practitioners. The two main reasons for not prescribing
vitamin D after the hip fracture of their patients were:
“Vitamin D was not prescribed at discharge” (53 %) and
“the patient does not want to take vitamin D” (20 %).
Discussion
With our study, we describe clinical application of vitamin D
supplementation in a large sample of hip fracture patients,
both at the time of their index hip fracture and after the event.
We show that supplementation is low prior to the index hip
fracture and remains low after the event. About 80 % of hip
fracture patients were not supplemented at any time point in
our study. Notably, we further confirm the high prevalence of
severe vitamin D deficiency in this population; confirm that
25-hydroxyvitamin D levels in hip fracture patients are low
also in the summer season, and that the 20 % who receive
supplementation have significantly higher 25-hydroxyvitamin
D levels. Finally, our substudy at 6 month follow-up among
general practitioners of not supplemented hip fracture patients
provides insight into why vitamin D is not prescribed even
after a hip fracture occurred. As the main reason stated was
“not mentioned in the discharge letter from acute care”, our
data suggest that surgeons need to become key partners of
post-hip fracture care as their recommendation, or lack of
recommendation is, according to our data, critical to whether
hip fracture patients receive vitamin D or not.
Mean 25-hydroxyvitamin D serum concentrations among
844 hip fracture patients of this study were 12.6 ng/ml; 80 %
were vitamin D deficient, and 52 % were severely deficient.
Furthermore, 25-hydroxyvitamin D levels upon admission
to acute care remained low in each month of the year,
without a significant rise during summer months. These data
confirm that hip fracture patients are most vulnerable to
vitamin D deficiency and need supplementation indepen-
dent of season. Moreover, the 19 % of patients who had any
dose of supplementation prior to their hip fracture had
significantly higher 25-hydroxyvitamin D levels, suggesting
that supplementation is effective as expected from a large
number of intervention studies in this population [31, 32].
The high prevalence of severe vitamin D deficiency
documented in our study suggests that clinical care with
884 (81%)
206 (19%)
628 (74%)
226 (26%)
252 (79%)
69 (22%)
226 (79%)
59 (21%)
Fig. 2 Prevalence of vitamin D Supplementation of any dose at the
time of hip fracture (admission to acute care), at discharge, and 6 and
12 months of follow-up. If we restrict this assessment to the 285
patients assessed at 12 months, 58 (20 %) received vitamin D prior
to admission due to the index fracture and 65 (23 %) received vitamin
D at 6 months. If we restrict this assessment to the 321 patients
assessed at 6 months, 70 (22 %) received vitamin D prior to admission
due to the index fracture
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respect to vitamin D supplementation both at the time of and
after hip fracture needs additional improvement. To further
guide clinical care, we investigated whether subgroups of
hip fracture patients are less likely to receive vitamin D
supplementation. Notably, before and after the index hip
fracture and independent of other covariates, men were
significantly less likely to receive vitamin D supplementa-
tion, although men and women had similarly low 25-
hydroxyvitamin D levels. This may have traditional reasons,
based on which men are thought to be at low risk of fracture.
However, more recent data show that among individuals age
60 years and older, the mortality-adjusted residual lifetime
risk of fracture is 44–65 % for women and 25–42 % for men
[33]. Furthermore, the benefit of vitamin D supplemen-
tation is confirmed for both men and women in recent
meta-analyses of fall and fracture prevention [13, 30,
34]. Also, hip fracture patients discharged to a nursing
home after the index hip fracture were 50 % less likely
to receive vitamin D supplementation in our study,
independent of other covariates. This speaks to a double
standard of care of nursing home and community-
dwelling seniors, which is not supported by the evi-
dence from the recent pooled analyses of double-blind
RCTs, where both community-dwelling (−32 %) and
institutionalized (−30 %) seniors benefited significantly
from high dose vitamin D supplementation (median
800 IU/day) in the prevention of hip fractures [13].
Adding to the case for vitamin D supplementation after
hip fracture, vitamin D supplementation reduced hospital
readmission in the first year after hip fracture significantly
by 39 % as demonstrated in the 173 trial participants [3] of
this study, independent of gender and type of dwelling.
Furthermore, in a secondary analysis of the same trial pop-
ulation, baseline 25-hydroxyvitamin D level was a signifi-
cant predictor of mortality in the first 12 months after hip
fracture, with a significant 7 % reduction in the risk of
mortality per 1 ng/ml higher 25-hydrocyvitamin D status
(per 1 ng/ml: HR=0.93; 95 % CI 0.87–0.998; p=0.04).
In a small substudy, we evaluated at the general practi-
tioners level why senior hip fracture patients did not receive
supplementation. Notably, the main reason for not prescrib-
ing vitamin D in their patients who sustained a hip fracture
was that this was not recommended in the discharge letter of
acute care. This information may be important, regarding
the choice of network partners of post-hip fracture care,
which according to our data should include traumatologists
and orthopedic surgeons, as they may have an important
impact on whether vitamin D is prescribed after hip fracture.
Our study has several strengths. The study population
included 1,090 consecutive hip fracture patients with assess-
ment of 25-hydroxyvitamin D levels in 844 confirming the
broad prevalence of deficiency and lack of seasonality as
observed in other studies of similar populations [20, 35–38].
Moreover, our initial sample can be linked to the results of a
Table 3 Adjusted associations between population characteristics and likelihood of receiving any dose of vitamin D per day (yes vs. no)
Baseline characteristic At the time of hip fracture (n=1,081)† At discharge from acute care‡ (n=848) 12 months (n=154**)
Gender
Male (Ref.) – – –
Female 2.26 1.78 2.61
(1.45–3.53) (1.17–2.70) (1.04–6.55)
Age, years.
65–84 (Ref.) – – –
85+ 1.10 1.01 0.95
(0.80–1.52) (0.73–1.40) (0.46–1.97)
Mini mental status (MMS)
≥15 (Ref.) – – –
<15 1.15 1.05 0.93
(0.80–1.66) (0.74–1.49) (0.41–2.09)
Dwellings
Home (Ref.) – – –
Nursing/old age home 1.01 0.50 0.63
(0.72–1.42) (0.35–0.71) (0.30–1.32)
(Asterisk) all associations are adjusted for gender, age, cognitive function at baseline, and type of dwelling (home or institutionalized); associations
for admission and discharge are additionally adjusted for the patient group (NFP-53, cohort study, or screened only). Analysis for 12 months of
follow up is limited to the hip fracture cohort participants. (Dagger) effective sample sizes are given for each time point. Some participants were
excluded from the models due to missing values in one or more of the predictors. (Double dagger) RCT participants are excluded, (double asterisk)
living condition at 12 month follow-up was missing on 131 patients; and since it was a logistic model, these patients were excluded from the model,
bringing the effective sample size to 154. All other covariates in the model have complete information on the entire sample size of 285
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double-blind RCT among the 173 trial participants who
were part of the 1,090 hip fracture patients surveyed in our
study [3]. Finally, we extend the assessment of vitamin D
supplementation in clinical practice to reasons why supple-
mentation is not prescribed at the general practitioner level.
This study also has limitations, as we were able to include
only a subsample at the 12 month follow-up assessment.
However, gender distribution and mean 25-hydroxyvitamin
D status were similar in the 427 hip fracture patients who
were prescreened but not enrolled into the cohort study or
the trial. Also, we adjusted our analyses for the covariates
that showed a variation between the three groups of partic-
ipants (age, cognitive status, and type of dwelling).
In summary, our results show that vitamin D supple-
mentation needs further support in its translation into
clinical practice, both in the primary prevention of hip
fractures and in post-hip fracture care. Efforts to im-
prove vitamin D supplementation in post-hip fracture
care will need an interdisciplinary approach, including
traumatology and orthopedic surgery to set up vitamin
D supplementation strategies effectively. Currently, over-
all vitamin D supplementation is too low, especially so
in senior men and nursing home residents.
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